Bionical Limited, a prominent player in the life sciences sector, is headquartered in Great Britain and operates extensively across Europe and North America. Founded in 2015, the company has rapidly established itself as a leader in providing innovative solutions for the pharmaceutical and biotechnology industries. Bionical Limited specialises in a range of services, including clinical trial support, patient recruitment, and market access strategies, all designed to enhance the efficiency of drug development. Their unique approach combines advanced technology with deep industry expertise, ensuring tailored solutions that meet the specific needs of their clients. With a strong market position, Bionical Limited has achieved significant milestones, including partnerships with major pharmaceutical companies and recognition for their commitment to quality and innovation in the life sciences arena.
How does Bionical Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bionical Limited's score of 21 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Bionical Limited reported significant carbon emissions, with a total of approximately 1,202,270,481 kg CO2e attributed to Scope 3 emissions, primarily from business travel. Additionally, the company recorded Scope 2 emissions of about 24,348 kg CO2e. Notably, Bionical Limited does not disclose any Scope 1 emissions data. Despite the substantial emissions figures, there are currently no documented reduction targets or climate pledges from Bionical Limited. The absence of specific initiatives or commitments indicates a potential area for improvement in their climate strategy. The company operates within the context of increasing industry pressure to adopt more robust climate action plans and set science-based targets for emissions reduction.
Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Business Travel" representing nearly all of their reported Scope 3 footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bionical Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
